TY  - GEN
AU  - Chatterjee,M
AU  - Turner,D C
AU  - Felip,E
AU  - Lena,H
AU  - Cappuzzo,F
AU  - Horn,L
AU  - Garon,E B
AU  - Hui,R
AU  - Arkenau,H-T
AU  - Gubens,M A
AU  - Hellmann,M D
AU  - Dong,D
AU  - Li,C
AU  - Mayawala,K
AU  - Freshwater,T
AU  - Ahamadi,M
AU  - Stone,J
AU  - Lubiniecki,G M
AU  - Zhang,J
AU  - Im,E
AU  - De Alwis,D P
AU  - Kondic,A G
AU  - Fløtten,Ø
TI  - Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
SN  - 1569-8041
PY  - 2017///1227
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - B7-H1 Antigen
KW  - genetics
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - pathology
KW  - ErbB Receptors
KW  - Female
KW  - Gene Expression Regulation, Neoplastic
KW  - drug effects
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
UR  - https://doi.org/10.1093/annonc/mdw174
ER  -